Masimo Corp Stock Price, News & Analysis

Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, has appointed Jon Coleman as Chief Commercial Officer. Coleman brings over 30 years of global commercial leadership experience and will oversee Dexcom's global commercial organization, including sales, marketing, and customer experience.

Coleman previously served as an executive officer at Masimo (NASDAQ: MASI) for 15 years, where he was president of commercial teams. He managed worldwide hospital sales, OEM, alternate care sales, clinical teams, and customer service. Prior to Masimo, Coleman held leadership positions at Pfizer (NYSE: PFE) Consumer Healthcare, including vice president and general manager of Canada and the Caribbean region, with additional experience in Asia and Latin America.

Throughout his career, Coleman has demonstrated success in scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.

Masimo (NASDAQ: MASI) has announced its participation in the 46th Annual Raymond James Institutional Investor Conference. The company's management will present on Tuesday, March 4, 2025 at 11:35 a.m. Eastern time. Investors and interested parties can access a live webcast of the presentation through Masimo's website. Additionally, a replay of the webcast will be made available after the live presentation concludes.

Masimo (MASI) reported its Q4 and full-year 2024 financial results, showing mixed performance across segments. Q4 consolidated revenue reached $601 million, up 9% year-over-year, with healthcare revenue at $368 million (+8%) and non-healthcare revenue at $232 million (+11%).

For full-year 2024, consolidated revenue was $2,094 million (+2%), with healthcare revenue growing 9% to $1,395 million, while non-healthcare revenue declined 10% to $699 million. The company reported a GAAP net loss per basic share of ($5.72), impacted by goodwill and intangibles impairment for Sound United. However, non-GAAP earnings per diluted share grew 16% to $4.40.

Looking ahead, Masimo's 2025 guidance projects healthcare revenue between $1,500-$1,530 million (+8-11%), with non-GAAP earnings per diluted share estimated at $5.10-$5.40.

Masimo (NASDAQ: MASI) has announced significant leadership changes effective February 12, 2025. Katie Szyman, currently worldwide president of Advanced Patient Monitoring at BD, has been appointed as the new CEO. Michelle Brennan, who served as Interim CEO, has been named Chairman of the Board, while Lead Independent Director Quentin Koffey becomes Vice Chairman.

Szyman brings over 35 years of experience, notably leading Edwards Lifesciences' Critical Care product group before its acquisition by BD in September 2024. Her appointment follows an extensive search process by Korn Ferry. The Board selected Szyman for her track record in accelerating revenue growth, experience in bringing new patient monitoring products to market, and success in leading industry talent.

The Board continues its previously announced strategic review of alternatives for both consumer audio and consumer healthcare businesses, with Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as legal advisor.

Masimo (MASI) has released preliminary financial results for Q4 and full-year 2024, along with 2025 guidance. Q4 2024 consolidated revenue is expected to reach $601 million, showing 9% growth. This includes healthcare revenue of $368 million (+8%) and non-healthcare revenue of $232 million (+11%).

For full-year 2024, consolidated revenue is anticipated at $2,094 million (+2%), with healthcare revenue at $1,395 million (+9%) and non-healthcare revenue at $699 million (-10%). Non-GAAP earnings per diluted share is expected to exceed $4.10, reaching the high end of previous guidance.

Looking ahead to 2025, Masimo projects healthcare revenue between $1,500-1,530 million (8-11% growth), Non-GAAP operating profit of $398-406 million (26.5% margin), and Non-GAAP earnings per diluted share of $4.90-5.10. The company is excluding Sound United from non-GAAP measures due to ongoing separation plans.

Masimo (MASI) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company's management will present on Thursday, January 16, 2025, at 10:30 a.m. Pacific time. Investors and interested parties can access a live webcast of the presentation through Masimo's website. For those unable to attend the live session, a replay will be made available on the company's website following the presentation.

Masimo (NASDAQ: MASI) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 8:30 a.m. Eastern time. Interested parties can access a live webcast of the presentation through the company's website at www.masimo.com. The company will also make a replay of the webcast available after the live presentation concludes.

Masimo (NASDAQ: MASI) has announced its participation in the upcoming Jefferies London Healthcare Conference. The presentation is scheduled for Thursday, November 21, 2024, at 8:30 a.m. GMT. Interested parties can access a live webcast of the presentation through Masimo's website. For those unable to attend the live session, a replay will be made available on the company's website following the presentation.

Masimo (NASDAQ: MASI) has announced its participation in the upcoming Stifel 2024 Healthcare Conference. The company's management will present on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. Interested parties can access a live webcast of the presentation through Masimo's website. A replay option will be available after the live presentation concludes.